Silexion Therapeutics to Present KRAS-Targeting RNAi Therapy at Boston Summit
Event summary
- Silexion Therapeutics will attend the 7th RNAi-Based Therapeutics Summit in Boston from January 27-29, 2026.
- CEO Ilan Hadar and management will host one-on-one meetings with interested parties.
- Silexion is developing SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes.
- Phase 2/3 clinical study for SIL204 in locally advanced pancreatic cancer planned for mid-2026.
The big picture
Silexion's participation in the RNAi-Based Therapeutics Summit underscores the growing focus on RNA-based therapies for oncology. The company's KRAS-targeting approach positions it in a competitive but high-potential segment of the market. Success in mid-2026 Phase 2/3 trials could significantly alter the landscape for pancreatic cancer treatments.
What we're watching
- Clinical Progress
- Whether SIL204 can demonstrate efficacy in Phase 2/3 trials for pancreatic cancer.
- Competitive Positioning
- How Silexion differentiates itself in the crowded RNAi therapeutics space.
- Investor Sentiment
- The impact of summit discussions on potential partnerships or funding opportunities.
Related topics